|1.||Aaby, Peter: 33 articles (01/2015 - 04/2002)|
|2.||Poland, Gregory A: 15 articles (12/2015 - 01/2003)|
|3.||Garly, May-Lill: 14 articles (06/2014 - 11/2002)|
|4.||Ovsyannikova, Inna G: 12 articles (12/2015 - 05/2003)|
|5.||Benn, Christine Stabell: 12 articles (01/2015 - 04/2002)|
|6.||Centers for Disease Control and Prevention (CDC): 12 articles (11/2014 - 05/2003)|
|7.||Jacobson, Robert M: 12 articles (10/2014 - 01/2003)|
|8.||Rodrigues, Amabelia: 12 articles (09/2014 - 06/2003)|
|9.||Griffin, Diane E: 11 articles (01/2014 - 01/2002)|
|10.||Benn, Christine S: 10 articles (01/2015 - 01/2010)|
11/01/1995 - "The introduction of live attenuated measles vaccine in Israel during 1967 dramatically decreased the incidence of measles. "
12/01/1992 - "Our experience has highlighted three important areas for future measles elimination: (1) the need for serological evaluation of vaccinees, particularly those who were born during the introduction of mass immunization; (2) improvement in measles vaccine efficacy; and (3) further investigations on the role of asymptomatic transmission and susceptibles who remain after mass immunization."
09/01/2011 - "The Region of the Americas eliminated measles in 2002 through high first-dose routine measles vaccine coverage and vaccination campaigns every 4-6 years; a second routine dose at school entry was added in some countries. "
01/01/2001 - "Better understanding of the mechanisms of immune suppression after measles, the potential for alternative vaccination strategies to induce immunity in young infants, and the immunologic basis of atypical measles, increased mortality after high-titer measles vaccine, and waning immunity will lead to improved strategies for measles control and elimination."
09/01/1998 - "Administration of standard-titre Edmonston-Zagreb measles vaccine at 6-8 months is an effective and safe preventive measure for measles, especially where the age-specific attack rate for children < 9 months is high."
06/01/1994 - "Infection of leucocytes by measles vaccine viruses Edmonston-Zagreb and Enders-Moraten has different consequences: potential mechanism for increased vaccine efficacy or aberrant activity in field trials."
01/15/2015 - "Measles virus (MV) infection is undergoing resurgence and remains one of the leading causes of death among young children worldwide despite the availability of an effective measles vaccine. "
07/01/2011 - "Risk of unintentional reintroduction from any source, including persistent infections and laboratory materials is low to very low but depends on the extent of measles vaccine use. "
04/01/2003 - "These findings indicate a central role for CD8(+) lymphocytes in the control of measles virus infections and the importance of eliciting a cell-mediated immune response in new measles vaccine strategies."
02/01/2003 - "Prior to the introduction of measles vaccine, the majority of the population acquired immunity through infection with wild-type virus in early childhood. "
01/01/2012 - "The live BCG and measles vaccine protects against more mortality than can be ascribed to the prevention of tuberculosis and measles, respectively. "
03/01/1962 - "Measles vaccine in children with asthma and tuberculosis."
01/01/2003 - "A recent article by Kristensen et al. suggested that measles vaccine and bacille Calmette-Gu rin (BCG) vaccine might reduce mortality beyond what is expected simply from protection against measles and tuberculosis. "
06/01/2014 - "In many situations, the population-based effects have been very different from the anticipated effects; for example, the measles-preventive high-titre measles vaccine was associated with 2-fold increased female mortality; BCG reduces neonatal mortality although children do not die of tuberculosis in the neonatal period; vitamin A may be associated with increased or reduced child mortality in different situations; effects of interventions may differ for boys and girls. "
12/01/1994 - "There is also a need for more efficient vaccines against tuberculosis, for a new measles vaccine effective in the young child in the presence of residual maternal antibodies. "
01/01/1981 - "The two main conclusions drawn from the study were: (1) two doses of poliomyelitis vaccine are inadequate to provide protection against poliomyelitis in developing countries; and (2) in developing countries measles vaccine should be given as soon as possible after the age of 8 months."
09/01/2003 - "We were performing a trial in which children were randomized at 6 months of age to receive either measles vaccine or inactivated polio vaccine. "
06/01/1993 - "In an urban area of Guinea-Bissau, 384 children were enrolled in a randomized trial comparing morbidity and mortality rates after receiving high-titer Edmonston-Zagreb (EZ) measles vaccine administered from 4 months of age, with a control group receiving inactivated poliomyelitis vaccine at 4 months of age and the standard Schwarz vaccine from 9 months of age. "
11/01/2014 - "Vaccine acceptance ranged from 87%-94%; among households rejecting polio vaccine, 38% of mothers sought measles vaccine for their children. "
01/01/2013 - "Children are considered fully immunized if they receive one dose of BCG, three doses of DPT and polio vaccine each, and one measles vaccine. "
|5.||Distemper (Canine Distemper)
01/01/1973 - "[Assessment of the efficacy of a heterologous (measles) vaccine against distemper]."
10/08/1994 - "A comparison of canine distemper vaccine and measles vaccine for the prevention of canine distemper in young puppies."
01/10/1976 - "Combined distemper/measles vaccine."
01/04/1975 - "Letter: Combined distemper/measles vaccine."
11/09/1974 - "Combined distemper-measles vaccine: advantage or disadvantage?"
|3.||Diphtheria-Tetanus-Pertussis Vaccine (DPT Vaccine)
|4.||Immunoglobulin G (IgG)
|6.||Vitamin A (Retinol)
|8.||Tetanus Toxoid (Vaccine, Tetanus)
|9.||Typhoid-Paratyphoid Vaccines (Typhoid Vaccines)
|1.||Nutritional Support (Artificial Feeding)
|3.||Highly Active Antiretroviral Therapy (HAART)